Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	KREJČÍ Marta MAYER Jiří DOUBEK Michael BRYCHTOVÁ Yvona POSPÍŠIL Z RÁČIL Zdeněk DVOŘÁKOVÁ Dana LENGEROVÁ Martina HORKÝ Ondřej KOŘÍSTEK Zdeněk DOLEŽAL T VORLÍČEK Jiří
Year of publication	2006
Type	Article in Periodical
Magazine / Source	Bone Marrow Transplantation
MU Faculty or unit	Faculty of Medicine
Citation
Keywords	chronic myeloid leukemia; allogeneic stem cell transplantation; imatinib
Description	A reduced-intensity conditioning allogeneic stem cell transplantation was given to 19 patients (aged 15 - 59 years) in the first chronic phase and one patient in the accelerated phase with chronic myeloid leukemia (CML) after a regimen consisting of fludarabine (Flu), busulfan (Bu) and ATG Fresenius. The median follow-up was 27 months. The incidence of acute and chronic graft-versus-host disease (GvHD) was 55 and 75%, respectively. Two patients (10%) died from GvHD. Fourteen (70%) patients achieved molecular remission. Additional post-transplant intervention (donor lymphocyte infusion, imatinib) was necessary, however, in 10 patients (50% of the patients; non-achievement of stable molecular remission or later relapses). The total direct cost of the transplantation treatment for all of the patients came to 1 572 880 euro. If the patients had been treated with imatinib and followed-up with the same time period as they were following a transplantation, the direct cost of the imatinib treatment would have been 2 005 117 euro. The transplantation treatment appears to be less expensive after approximately 2 years of follow-up. Flu+Bu+ATG is a low-toxicity regimen for patients with CML. However, a close follow-up is necessary and about 50% of the patients require further therapeutic intervention.